YHYanglin Hu

Yanglin Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanglin Hu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Xiong

    Department of Nephrology, Wuhan No.1 Hospital, Wuhan, China

    6 shared publications
  • Sheng Wan

    Department of Nephrology, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications
  • Can Tu

    Department of Nephrology, Wuhan No.1 Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Li Xu

    Department of Nephrology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Mingjun Shi

    Department of Nephrology, Yichang Central People’s Hospital, Yichang, China

    2 shared publications
  • Qian Huang

    Department of Nephrology, Yichang Central People’s Hospital, Yichang, China

    2 shared publications

Latest Publications

  • Open Access

    Effectiveness and renal safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis patients with chronic kidney disease stages 4–5: a real-world cohort study in China

    by Gang Hu, Quanhong Zhang, Luoyao Yang, Yanglin Hu, Jinbo Chen

    Background: While dupilumab is widely used for atopic dermatitis (AD), its safety and effectiveness in patients with severe renal failure remain insufficiently studied. Objective: To evaluate the real-world effectiveness and renal safety of dupilumab in this population. Methods: This cohort study included 30 adult moderate-to-severe AD patients with Chronic Kidney Disease (CKD) stages 4–5. Patients were divided into a dupilumab-treated group ( n = 17) and a control group ( n = 13) receiving conventional therapy. Effectiveness was assessed using the Peak Pruritus Numerical Rating Scale and Investigator's Global Assessment. Renal safety was evaluated via eGFR and serum creatinine levels, analyzed using linear mixed-effects models. Results: The dupilumab group showed a numerically greater PP-NRS reduction at Day 30 (4.6 vs. 2.7 points) with a trend toward sustained improvement; however, the between-group difference did not reach statistical significance in the mixed-effects model ( P = 0.109). IGA scores showed similar trends. Regarding renal safety, despite poorer baseline renal function in the dupilumab group, the degree of renal function decline was not statistically different from that in the control group. Sensitivity analysis excluding patients on dialysis did not alter this conclusion. Conclusion: Dupilumab was associated with a numerical trend toward greater improvement in pruritus compared with conventional therapy, and was not associated with statistically detectable acceleration of renal function decline in AD patients with CKD stages 4–5. These preliminary findings require confirmation in larger prospective studies.

  • Open Access

    Long-term survival and mortality characteristics of patients with ANCA-associated vasculitis on maintenance hemodialysis: a propensity score-matched study from the Wuhan registry (2017–2025)

    by Yanglin Hu, Sheng Wan, Yonglong Min, You Song, Danni Shao, Mingjun Shi, Qian Huang, Can Tu, Fei Xiong

    Registry-based data on the long-term survival of ANCA-associated vasculitis (AAV) patients on maintenance hemodialysis (MHD) in China are limited, particul

  • Open Access

    Urinary complement C3 fragment levels and their clinical relevance in MPO-ANCA-associated vasculitis

    by Yanglin Hu, Mingjun Shi, Qian Huang, Sheng Wan, Miao Zhang, Zengsi Wang, Wei Huang, Shuang Zhang, Fei Xiong

    Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease characterized by systemic small-vessel inflammation. Complement activation, particularly through the alternative pathway, has been implicated in AAV pathogenesis. However, the role and clinical significance of urinary complement C3 fragments as non-invasive biomarkers for disease activity remain unclear. This cross-sectional study enrolled 22 AAV patients and 20 healthy controls. Urinary levels of C3a, C3b, iC3b, C3c, and C3d were measured using enzyme-linked immunosorbent assay (ELISA) and normalized to urinary creatinine. Between-group comparisons were performed using independent t-tests or Mann–Whitney U tests. Correlations and independent predictors of urinary complement fragments were evaluated using Spearman correlation and multivariate linear regression, respectively. All urinary complement C3 fragment levels were significantly elevated in AAV patients compared to healthy controls (all p < 0.01). Among AAV patients, urinary C3 fragments correlated strongly with Birmingham Vasculitis Activity Score (BVAS, r = 0.793–0.900), proteinuria (r = 0.551–0.735), and hematuria (r = 0.643–0.752) (all p < 0.01), but not with serum creatinine (p > 0.05). BVAS was an independent predictor of all C3 fragments (β = 0.458–0.760, all p < 0.05), while proteinuria independently predicted all except iC3b (β = 0.302–0.455, all p < 0.05). Urinary complement C3 fragments are elevated in AAV patients and closely associated with disease activity, independent of renal function. These findings support their potential utility as non-invasive biomarkers for monitoring AAV disease activity.


  • Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli

    by Peiqi Hu, Hong Xiao, Marco A. Alba, Hannah M. Atkins, Shenju Gou, Yanglin Hu, John C. Gomez, Corey M. Jania, Jessica R. Martin, Thomas E. Morrison, et al.


  • Open Access

    Case Report: Identification of a Novel Heterozygous Missense Mutation in COL4A3 Gene Causing Variable Phenotypes in an Autosomal-Dominant Alport Syndrome Family

    by Yanglin Hu, Wei Li, Lulu Tian, Shuai Fu, Yonglong Min, Jia Liu, Fei Xiong

    Alport syndrome (AS) is a genetic kidney disease of basement membrane collagen disorder accounting for approximately 2% of ESRD patients. Next-generation and whole-exome sequencing methods are increasingly frequently used as an efficient tool not only for the diagnosis of AS but also for the establishment of genotype–phenotype correlation. We herein report the identification of a novel heterozygous missense mutation in COL4A3 gene (c.G3566A: p.G1189E) causing variable phenotypes in an ADAS Family based on the combination of clinical, histologic, pedigree, and genetic sequencing information. The proband is a 48-year-old Chinese woman suffering from persistent subnephrotic proteinuria and intermittent hematuria without renal function impairment over a 10-year time-span. Renal biopsy showed diffuse thin basement membrane and focal interstitial foam cell infiltration. The proband’s mother progressed to end-stage renal failure and the proband’s sister presented with subnephrotic proteinuria and intermittent hematuria as well. AS was highly suspected and confirmed by exome sequencing which revealed a novel heterozygous missense mutation in COL4A3 gene (c.G3566A: p.G1189E) in all the affected family members, although their current medical conditions vary significantly. Our present finding emphasizes the significance of next-generation sequencing technology for genetic screening which gives us an accurate clinical diagnosis of ADAS patients. The identification of c.G3566A as a new ADAS-related mutation contributes to both genetic diagnosis of ADAS and further functional study of COL4A3. The variable phenotypes from the same genotype of our case also provide more information to genotype–phenotype correlation study.

  • Changes before and after COVID-19 pandemic on the personal hygiene behaviors and incidence of peritonitis in peritoneal-dialysis patients: a multi-center retrospective study

    by Yanglin Hu, Li Xu, XiaoHui Wang, Xiaofei Qin, Sheng Wan, Qing Luo, Yanqiong Ding, Xiaofen Xiao, Fei Xiong

    Background The impact of Coronavirus disease (COVID-19) pandemic and its influence on personal hygiene behaviors and peritonitis rate in peritoneal-dialysis patients is unknown. Methods A multi-center retrospective study was conducted. We reviewed all the cases of peritoneal-dialysis (PD) patients from four major PD centers in Wuhan before and after COVID-19. There were 567 patients enrolled in total. Information was collected on personal hygiene behaviors, basic clinical characteristics, lab results, peritonitis details. We used Chi-square analysis to compare the personal hygiene behaviors, and used Chi-square goodness-of-fit analysis to compare the peritonitis rates before and after COVID-19. Multivariate logistic regression analysis was used to analyze the risk factors for peritonitis rate. Results There were no significant differences on peritonitis rates in six-month period before and after COVID-19 (p = 0.0756, Fig. 2 and Table 3). But Gram-positive infections decreased dramatically (p = 0.0041, Table 4). Personal hygiene behaviors such as length of time for washing hands when performing PD treatment, the frequency of washing hands before PD treatment and six general behaviors had significant differences (P < 0.05 Table 2). The multivariate logistic regression analysis showed never washing hands before PD treatment and serum albumin level were the risk factors of peritonitis during COVID-19 (OR 14.408, 95%CI 3.930 –52.821, P = 0.0002; OR 4.681, 95% CI 1.755 –12.485, P = 0.002, Table 5). Conclusions The COVID-19 pandemic had a significant positive influence on personal hygiene behaviors. Peritonitis rate did not significantly decrease but Gram-positive infections dramatically decreased. Never hand washing before PD treatment and serum albumin were the risk factors for peritonitis. We should emphasize hand washing before PD treatment in training and re-training program.


  • Open Access

    Bed‐sided short‐duration renal replacement therapy provide a possible option to treat non‐critical coronavirus disease 2019 in maintenance hemodialysis patients in public health crisis

    by Yanglin Hu, Can Tu, Jun‐Wu Dong, Wen‐Li Chen, Xiao‐Hui Wang, Dan Luo, Ming Shi, Mengliang Zhou, Yuting Song, Chun Zhang, et al.

    HD care may experience great stress with the coronavirus disease 2019 (COVID‐19) pandemic. A modified HD modality named bed‐sided short‐duration renal replacement therapy (BSRRT) was used in noncritical maintenance HD (MHD) patients diagnosed with COVID‐19 in Wuhan due to extreme situation. To determine the safety and efficacy as a substitution for intermittent HD (IHD), we conducted this study. We used the data of 88 noncritical COVID‐19 MHD patients collected from 65 medical units at the hospitals in Wuhan, China, from January 1 to March 10, 2020. t‐test, Wilcoxon rank sum test, and Fisher exact probability method were used to compare the baseline characteristics, treatment, and death. Log‐rank test and Cox regression multivariate analysis was used to compare the survival of noncritical patients who were transferred to BSRRT modality versus those who were continued on the IHD. Univariate analysis showed the level of reported fatigue symptom at present, bilateral lung computed tomography infiltration and steroid treatment differed between the two groups. The outcome of death of the two groups did not show significant differences in univariate analysis (P = .0563). Multivariate Cox regression analysis dialysis showed modality of treatment after COVID‐19 diagnosis was not a significant predictor of death (P = .1000). These data suggest that for noncritical COVID‐19 MHD patients, the transfer from IHD to BSRRT does not have significant difference in the risk of death compared with IHD group. This finding suggests this modified modality could be an option for the substitution for IHD during the COVID‐19 pandemic period.